Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

DOI: 10.1158/1078-0432.CCR-14-1993 Published March 2015

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1.
Ad hoc semiquantitative scoring scheme for PD-L1 expression by tumor cells in RCC (A) and example of prominent peripheral inflammatory response and corresponding PD-L1 expression (B).
Download figure
Open in new tab
Download powerpoint
Figure 2.
Association of OS with PD-L1 expression status on tumor cell membrane.

Table 1.

Patient characteristics

Characteristic	Pazopanib (N = 221)	Sunitinib (N = 232)
Median age, y (range)	62 (30–86)	62 (33–86)
Sex, n (%)
Male	158 (71)	178 (77)
Female	63 (29)	54 (23)
Prior nephrectomy, n (%)	191 (86)	205 (88)
KPS, n (%)
70 or 80	57 (26)	60 (26)
90 or 100	164 (74)	169 (74)
LDH, n (%)
>1.5× ULN	17 (8)	11 (5)
≤1.5× ULN	204 (92)	214 (95)
Metastatic sites at baseline, n (%)
≤2	151 (68)	152 (65)
>2	70 (32)	80 (34)
MSKCC risk category, n (%)
Favorable	64 (29)	55 (24)
Intermediate	127 (57)	142 (61)
Poor	26 (12)	24 (10)
Unknown	4 (2)	11 (5)

Abbreviation: ULN, upper limit of the normal range.

Table 3.

Comparison of PD-L1 expression between full tissue sections and core biopsies

Supplementary Data

Files in this Data Supplement:

Supplementary Table S1, Figures S1-2 - Supplementary Table S1, Figures S1-2. Supplementary Table S1. Comparison of treatment outcomes between the overall study population of the COMPARZ trial and the PD-L1 study population. Supplementary Figure S1. CD8+ T cells scoring system. Supplementary Figure S2. Association of overall survival (OS) with PD-L1 expression status on tumor cell membrane.